Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1

Antiviral Therapy

Volumn 13, Issue 6, 2008, Pages 839-843

  Viganò, Alessandra ^a   Meroni, Luca ^b   Marchetti, Giulia ^b   Vanzulli, Angelo ^c   Giacomet, Vania ^c   Fasan, Silvia ^a   Pradella, Andrea ^a   Cerini, Chiara ^a   Zuccotti, Gian V ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DARUNAVIR; DIDANOSINE; ENFUVIRTIDE; ETRAVIRINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RITONAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOCYTE COUNT; MALE; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRIDAZINES; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 53149131341     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Welles SL, Bauer GR, La Russa PS, et al. Time trends for HIV-1 antiretroviral resistances among antiretroviral-experienced and naive pregnant women in New York City during 1991 to early 2001. J Acquir Immune Defic Syndr 2007; 44:329-335.
2. Palumbo P, Holland B, Dobbs T, et al. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected omen and their newborns in the United States: vertical transmission and clades. J Infect Dis 2001; 184:1120-1126.
3. Bauer GR, Colgrove RC, La Russa PS, Pitt J, Welles SL for the Women and Infants Transmission Study Team. Antiretroviral resistance in viral isolates from HIV-1-transmitting mothers and their infants. AIDS 2006; 20:1707-1712.
4. Cohan D, Feakins C, Wara D, et al. Perinatal transmission of multidrug resistance HIV-1 despite viral suppression on an enfuvirtude-based treatment regimen. AIDS 2005; 19:989-990.
5. Desai N, Mathur M. Selective transmission of multidrug resistance HIV to a newborn related to poor maternal adherence. Sex Transm Infect 2003; 79:419-421.
6. De Jose MI, Ramos JT, Alvarez S, Jimenez JL, Munoz-Fernandez MA. Vertical transmission of HIV-1 variants resistant to reverse transcriptase and protease inhibitors. Arc Intern Med 2001; 161:2738-2739.
7. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38.
8. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48.
9. Bologna R, Rugina S, Cahn P, et al. Darunavir evaluation in pediatric WI-1-infected treatment-experienced patients (Trial TMC 114-C212). 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 78LB.
10. Kakuda TN, Konig C, Felterna-Sperling C, et al. Pharmacokinetics of the next generation NRTI etravirine (ETR; TMC 125) in HIV-infected children between 6 and 17 years inclusive. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 762.
11. Viganò A, Vella S, Saresella M, et al. Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. AIDS 2000; 14:251-261.
12. Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemotber 2007; 59:1047-1056.
13. European Collaborative Study. Mother to child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:458-464.
14. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopiesis, and CD4 T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995; 332:143-149.
15. Autran B Carcelain B, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4 T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116.
16. Mussini C, Pinti M, Borgbi V, et al. Features of 'CD4-exploders', HIV ositive patients with an optimal immune reconstitution aiter potent antiretroviral therapy. AIDS 2002; 16:1609-1616.
17. Resino S, Seoane E, Perez A Ruiz-Mateos E, Leal M, Munoz-Fernandez MA. Diderent profiles of immune reconstitutions in children and adults with HIV-infection after of highly active antiretroviral therapy. BMC Infect Dis 2006; 6:112.
18. Fry TJ, Mackall CL. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol 2001; 22:564-571.